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Genetic polymorphisms contribute to inter-individual variability in the metabolism 
of multiple clinical drugs, including warfarin, thiopurines, primaquine, and 
aminoglycosides. A rapid and sensitive clinical assessment of various genome biomarkers 
is, therefore, required to predict the individual responsiveness of each patient to these 
drugs. In this study, we developed a novel genotyping method for the detection of nine 
pharmacogene variants that are important in the prediction of drug efficiency and toxicity. 
This genotyping method uses competitive allele-specific PCR and a single-stranded tag 
hybridization chromatographic printed-array strip (STH-PAS) that can unambiguously 
determine the presence or absence of the gene variant by displaying visible blue lines on 
the chromatographic printed-array strip. Notably, the results of our STH-PAS method 
were in 100% agreement with those obtained using standard Sanger sequencing and 
KASP assay genotyping methods for CYP4F2 gene deletion. Moreover, the results were 
obtained within 90 min, including the PCR amplification and signal detection processes. 
The sensitive and rapid nature of this novel method make it ideal for clinical genetic 
testing to predict drug efficacy and toxicity, and in doing so will aid in the development 









Differences in an individual’s response to a drug and the occurrence of adverse 
reactions have been associated with various factors, such as age, sex, concomitant drugs, 
diet, smoking, and genetic polymorphisms [1, 2]. It is widely known that genetic 
polymorphisms in genes that encode proteins involved in drug absorption, distribution, 
metabolism, and excretion often cause issues with drug efficacy or increase toxicity [3]. 
Indeed, single nucleotide variations at the loci for cytochrome P450 (CYP) 2C9, vitamin 
K epoxide reductase complex 1 (VKORC1), CYP4F2, nudix protein 15 (NUDT15), ATP-
binding cassette sub-family C member 4 (ABCC4), glucose-6-phosphate dehydrogenase 
(G6PD), and mitochondrial DNA (mtDNA) have been shown to influence the drug 
response [4-8]. The field of pharmacogenetics largely focuses on determining the 
influence of these gene variations and uses this information to customize drug class, 
optimal dose, and dosage regimen for individual patients. 
Before drug treatment, it is extremely desirable to use bedside genotyping methods 
to identify drug responders or non-responders as well as to identify patients with an 
increased risk of toxicity. Currently, numerous polymerase chain reaction (PCR)-based 
genotyping methods have been developed, including PCR-restriction fragment length 
polymorphism, allele-specific PCR, and TaqMan PCR [9-12]. However, each of these 
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techniques requires expensive instrumentation and extensive technical expertise to obtain 
reliable, reproducible results. 
Recently, Tian et al. developed a single-stranded tag hybridization chromatographic 
printed-array strip (STH-PAS) genotyping method [13]. This method allows multiplex 
DNA signals to be visualized in a single reaction with high sensitivity in a markedly short 
time. Moreover, it does not require the preparation or staining of cumbersome gels. 
Furthermore, Saito et al. recently reported a rapid and sensitive multiplex single-tube 
nested PCR method using STH-PAS for the identification of five human Plasmodium 
species [14]. While this technique has been investigated for various applications, it has 
not been evaluated for its use as a pharmacogene identification method. 
In this study, we developed a multiplex single-tube PCR assay to genotypically 
identify common pharmacogene variants, including warfarin (WRF)-related gene 
polymorphisms (CYP2C9*3, VKORC1 -1639G>A, CYP4F2*3, and CYP4F2 gene 
deletion), thiopurine-related gene polymorphisms (NUDT15*3 and ABCC4 c.2268G>A), 
mtDNA 1555A>G, and G6PD gene polymorphisms (c.202G>A and c.376A>G). To our 
knowledge, this is the first time this novel method has been applied to rapidly and 




Materials and Methods 
Sample collection 
Subject samples of each desired genotype were collected from unrelated Japanese 
(n = 180; 60 for WRF-related, 60 for thiopurine-related, and 60 for mtDNA). Additionally, 
Kenyan samples (n = 52) containing the polymorphisms 202G>A and 376A>G were 
obtained in order to verify the functionality of STH-PAS. Genomic DNA was isolated 
from peripheral blood samples (Japanese individuals) or three blood spot-containing discs 
(6 mm in diameter) (Kenyan individuals) using a QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany). Genomic DNAs with rare variants were also prepared from an Epstein-Barr 
virus-immortalized cell line established in Tohoku Medical Megabank Organization using 
a Gentra Puregene Blood Kit (Qiagen, Hilden, Germany) [15]. This study was conducted 
in accordance with the Declaration of Helsinki and the participants provided written 
informed consent according to the protocols approved by the Osaka City University 
committee (permission number 3206), the Tohoku University Graduate School of 
Pharmaceutical Sciences committee (permission number 15-03), and the Tohoku Medical 






The following GenBank genomic sequences were used as reference sequences: 
CYP2C9, NG_008385.1; VKORC1, NG_011564.1; CYP4F2, NG_007971.2; NUDT15, 
NG_047021.1; ABCC4, NG_050651.1; mtDNA, NC_012920.1; and G6PD, 
NG_009015.2. Primers were designed to specifically amplify each gene (Table 1). Primer 
pairs were checked using a BLAST search to confirm the absence of nonspecific 
amplification. For all primer pairs, a single primer was labeled with a tag-spacer sequence 
at its 5′ end for detection as shown in Figures 1A–1D, while the others were labeled with 
biotin at their 5′ ends. 
 
Genotyping of WRF-related genes polymorphisms 
Multiplex single-tube PCR amplification was performed with genomic DNA 
samples (10 ng), 2× KAPA2G Fast Multiplex Mix (Kapa Biosystems, Wilmington, MA, 
USA), and a mixture containing each primer at a concentration of 0.1 µM 
(VKORC1_Fw_Wt_G) or 0.2 µM (VKORC1_Fw_Vr_T, VKORC1_Rv, 
CYP2C9_Fw_Wt_C, CYP2C9_Fw_Vr_G, CYP2C9_Rv, CYP4F2_Fw_Wt, 
CYP4F2_Fw_Vr, CYP4F2_Rv, CYP4F2_Del_Fw, and CYP4F2_Del_Rv). The PCR 
conditions included an initial denaturation step at 95°C for 2 min; 30 cycles of 
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denaturation at 95°C for 30 s, annealing at 61°C for 20 s, and extension at 72°C for 30 s; 
and a final extension at 72°C for 7 min. 
STH-PAS was performed in a 20 µL reaction system containing 10 μL of 
developing solution (Tohoku Bio-Array, Sendai, Japan), 1 μL of PCR product, and 1 μL 
of streptavidin-coated blue latex suspension (Tohoku Bio-Array). The C-PAS12 
membrane stick (Tohoku Bio-Array) was dipped into the mixture for 10 min at 20–25°C. 
During this time, the blue latex particles coated with streptavidin interacted with the 
biotinylated terminal amplicons. A total of seven complementary oligonucleotides 
designed to specifically recognize the PCR amplicons through hybridization with the 5′ 
terminus tags were immobilized on the dipstick strips. The appearance of a visible blue 
test line indicated the presence of the target DNA sequence tagged with the 
complementary oligonucleotide. A biotin-immobilized flow control line was arranged at 
the end of each strip and functioned as an internal control to ensure the chromatographic 
migration of the solution. 
 
Genotyping of thiopurine-related genes polymorphisms 
Multiplex single-tube PCR amplification was performed with genomic DNA 
samples (10 ng), 2× KAPA2G Fast Multiplex Mix, and a mixture of primers at a 
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concentration of 0.1 µM (NUDT15_Fw_Wt, NUDT15_Rv, ABCC4_Fw_Wt, and 
ABCC4_Rv) or 0.2 µM (NUDT15_Fw_Vr and ABCC4_Fw_Vr). The PCR conditions 
included an initial denaturation step at 95°C for 3 min; 30 cycles of denaturation at 95°C 
for 30 s, annealing at 61°C for 30 s, and extension at 72°C for 30 s; and a final extension 
at 72°C for 7 min. STH-PAS was then performed as described above. The C-PAS8 
(Tohoku Bio-Array) membrane stick was dipped into the mixture for 10 min at 20–25°C. 
 
Genotyping of G6PD gene polymorphisms 
Multiplex single-tube PCR amplification was performed with genomic DNA 
samples (1 ng), 2× KAPA2G Fast Multiplex Mix (Kapa Biosystems), and a mixture of 
primers at a concentration of 0.05 µM (G6PD_202_Fw_Wt and G6PD_376_Fw_Vr) or 
0.1 µM (G6PD_202_Fw_Vr, G6PD_202_Rv, G6PD_376_Fw_Wt, and G6PD_376_Rv). 
The PCR conditions included an initial denaturation step at 95°C for 3 min; and then 30 
cycles of denaturation at 95°C for 30 s, annealing at 68°C for 30 s, and extension at 72°C 
for 30 s. STH-PAS was then performed as described above only with 2 μL of the 
streptavidin-coated blue latex suspension. The C-PAS4 membrane stick was dipped into 




Genotyping of mtDNA gene polymorphisms 
PCR amplification was performed with genomic DNA samples (10 ng), 2× SYBR 
Premix Ex Taq II (TaKaRa, Shiga, Japan), and a mixture of primers at a concentration of 
0.25 μM Mt_Fw_Wt_T; 0.25 μM Mt_Fw_Vr_T; and 0.25 μM Mt_Rv). The PCR 
conditions involved an initial denaturation step at 94°C for 2 min; 28 cycles of 
denaturation at 94°C for 30 s, annealing at 62°C (increasing 0.2ºC per cycle) for 20 s, and 
extension at 72°C for 30 s; and a final extension at 72°C for 7 min. STH-PAS was 
performed as described above. The C-PAS4 (Tohoku Bio-Array) membrane stick was 
dipped into the mixture for 5 min at 20–25°C. 
 
Statistical analysis 
The Kompetitive Allele Specific PCR (KASP) genotyping assay (LGC Genomics, 
Hertz, UK) for the CYP4F2 gene deletion variant [16] and Sanger sequencing-based 
genotyping were performed to evaluate the concordance rate for each genotyping method 
with all multiplex single-tube nested PCR methods. KASP assay was utilized as a unique 
form of allele-specific PCR that enables accurate bi-allelic scoring of single nucleotide 
polymorphisms, insertions, and deletions. The KASP genotyping reaction comprises 
sample DNA, KASP Assay mix (containing the target-specific primers), and KASP 
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Master mix. Unlike other PCR-based genotyping assays, KASP requires no labeling of 
the target-specific primers and probes, giving it a clear cost advantage. The 95% 
confidence intervals (CIs) were calculated using R version 3.0.3 (R core team (2014); R 





Representative results for our STH-PAS detection method-based genotyping are 
shown in Figure 2. There were no false positives or false negatives observed. There was 
a 100% match in the genotyping results for nine variants: CYP2C9 (CYP2C9*3, 
rs1057910), VKORC1 (-1639G>A, rs9923231), CYP4F2 (CYP4F2*3, rs2108622 and 
CYP4F2 gene deletion allele), NUDT15 (NUDT15*3, rs116855232), ABCC4 
(c.2268G>A, rs3765534), G6PD (c.202G>A, rs1050828 and c.376A>G, rs1050829), and 
mtDNA (1555A>G, rs267606617). Using sanger-sequencing and the KASP assay as the 
standard genotyping methods to detect CYP4F2 gene deletion, the concordance rates of 
STH-PAS genotyping for WRF-related genes (n = 60), thiopurine-related genes (n = 60), 
G6PD gene (n = 52), and mtDNA gene (n = 60) were 100% (95% CI = 94.0–100.0%, 





Variations in pharmacogenes that encode proteins involved in drug absorption, 
distribution, metabolism, and excretion have been known to influence inter-individual 
variability in drug efficacy and adverse drug reactions [1, 3]. These genetic 
polymorphisms can, therefore, be used as genome biomarkers to predict the 
responsiveness of each patient to specific drugs prior to treatment. This allows more 
effective and safer individualized drug treatment to be administrated as the therapeutic 
agents can be selected based on the gene polymorphisms present in each patient. While 
various methods have attempted to do this, they typically involve expensive equipment 
or significant expertise with the method [9-12]. In this study, we developed genotyping 
methods for WRF-related, thiopurine-related, G6PD (c.202G>A and c.376A>G), and 
mtDNA 1555A>G gene polymorphisms based on allele-specific PCR and STH-PAS, a 
recently established detection method. 
The STH-PAS has several advantages when compared to PCR-RFLP and other 
allele-specific PCR methods, including that in order to detect genetic variations, STH-
PAS requires little technical interpretation and provides results within 90 min, enabling 
rapid genotyping. Moreover, the cost of STH-PAS ranges from 7–8 dollars per sample, 
making it more economical for visualizing multiplex DNA. Generally, ethidium bromide 
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staining following gel electrophoresis is used to visualize PCR amplicons because of its 
simplicity and low cost. However, it poses the expected safety risks that accompany the 
use of a carcinogenic agent [17, 18]. Therefore, the STH-PAS genotyping method would 
allow for rapid genetic testing in a clinical setting. 
WRF, a widely prescribed anticoagulant, is administered as a racemic mixture of 
(S) and (R)-WRF for the long-term treatment and prevention of thromboembolic events 
[19]. Unfortunately, this drug is associated with significant inter-individual variability, 
particularly with regards to the dose required to produce a therapeutic effect [20, 21]. 
Recent genome-wide analyses have provided strong evidence that genetic polymorphisms 
can predict bleeding or the risk of thrombotic events, which occur with either an excessive 
or insufficient dose, respectively [22, 23]. In the Japanese patients in one study, the 
primary polymorphisms were CYP2C9*3, VKORC1 -1639G>A, and CYP4F2*3 [4]. As 
an anticoagulant, (S)-WRF, which is metabolized to 7-hydroxywarfarin by CYP2C9, is 
3–5 times more potent than (R)-WRF [24-26]. The CYP2C9*3 allelic variation appears 
to cause low (S)-WRF clearance, consequently increasing the risk of bleeding [27, 28]. 
The VKORC1 -1639G>A polymorphism in the promoter region decreases the enzymatic 
activity of the protein, which catalyzes the reduction of vitamin K epoxide to vitamin K 
[29]. Vitamin K is known to play an important role in blood coagulation [30]. In fact, 
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vitamin K hydroxylation, which is catalyzed by CYP4F2, has been shown to decrease 
coagulation [31]. It is, therefore, not surprising that the CYP4F2*3 mutation, which 
influences the oxidation activity of CYP4F2, also has an effect on WRF-mediated 
anticoagulation. Moreover, a novel CYP4F2 deletion variant was found in a Japanese 
study that accounts for 1.6% of this population [16]. Thus, analyzing the genetic 
polymorphisms that affect WRF-related anticoagulation therapy would be beneficial in 
attaining an approximate dosing regimen in Japanese patients. 
Thiopurines, including 6-mercaptopurine (6-MP), thioguanine, and azathiopurine, 
are commonly used to treat acute lymphoblastic leukemia and inflammatory bowel 
diseases [32, 33]. Notably, 6-thioguanine nucleotides (6-TGNs) are the main cytotoxic 
metabolites of thiopurines [34]. Recent studies have reported that NUDT15 and ABCC4 
genetic variants are significantly associated with thiopurine-induced toxicity in the Asian 
population [5], with NUDT15*3 (10.5%) and ABCC4 c.2268G>A (14.7%) being the most 
significant in the Japanese population reference panel [15, 35]. Almost all patients 
carrying these mutations showed severe 6-MP-associated toxicities [5, 36, 37]. Therefore, 
before selecting a therapeutic 6-MP dose, it would be beneficial to analyze NUDT15 and 
ABCC4 variants in the patients to prevent severe adverse effects. 
Malaria is caused by widespread prevalence of protozoan parasites of the genus 
17 
 
Plasmodium, and leads to health and economic burden in the Americas, the Western 
Pacific region, and South-east Asia [38]. A considerable number of people suffering from 
acute Plasmodium vivax malaria cannot safely undergo primaquine therapy to prevent 
recurrent relapses because of the risk of severe primaquine toxicity in patients with an 
inherent deficiency of G6PD [39-41]. G6PD deficiency affects more than 400 million 
people, approximately 8% of the general population in malaria-endemic nations [42]. The 
202G>A and 376A>G mutations are considered the most common G6PD deficiency 
alleles in sub-Saharan Africa [8]. In addition to the genotypic method developed in the 
present study to identify these G6PD genetic polymorphisms, a malaria species-specific 
diagnostic method using STH-PAS involving a multiplex single-tube nested PCR 
targeting Plasmodium mitochondrial cytochrome c oxidase III has also been recently 
reported [14]. Combining these G6PD polymorphism genotyping and malaria species-
specific diagnosis methods would greatly enhance the selection of therapeutic agents and 
dose adjustments to suit individual needs. Moreover, it might be possible to achieve a 
more appropriate antimalarial therapy by incorporating representative G6PD genetic 
polymorphisms to this genotyping method. 
Aminoglycosides have been used as effective antibiotics for both gram-positive and 
gram-negative infections [43]. The characteristic side effect associated with these drugs 
18 
 
is irreversible hearing loss observed in patients [44]. Recently, mtDNA mutations, 
including 1555A>G, have been shown to be responsible for aminoglycoside-induced 
deafness [6, 7]. The frequency of this mutation in patients who have aminoglycoside-
induced deafness was identified in various ethnic groups: Brazilian (1.3–3%), Japanese 
(3%), Danish (2.4%), German (0.7%), Polish (5.3%), and Southeast Asian (5.3%) [45]. 
However, in a previous study focused on 279 Asian individuals, aminoglycoside-induced 
deafness only occurred in patients with the 1555G mutation; all individuals with this 
mutation presented aminoglycoside-induced deafness [44]. Therefore, using our 
genotyping method before drug administration could enable prevention of this serious 
adverse effect in patients carrying the 1555G mutation. Moreover, because mtDNA 
exhibits a maternal inheritance pattern in mammals, genotyping results could also be 
relevant for blood relatives, including the patient’s brothers and sisters. 
In conclusion, we have described and tested an allele-specific PCR and STH-PAS 
method for the detection of well-known genetic polymorphisms involved in the efficacy 
and toxicity of various drugs. This method would be valuable in the improvement of 
pharmacotherapies with the use of WRF and thiopurine in Japanese patients. 
Simultaneously, this study also shows that it is possible to perform mtDNA genotyping 
by using this method in much the same way as its potential application in G6PD 
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genotyping using representative G6PD mutations, in malaria-endemic nations. 
Additionally, the STH-PAS method would be expected to be developed for other 
clinically important genetic polymorphisms such as CYP2C19 (*2, *3) and UGT1A1 (*6, 
*28). Notably, the genotyping results obtained using our method were 100% similar to 
those obtained using standard Sanger sequencing. However, one limitation of our method 
is that the combination of all genotypes cannot be confirmed because of low allele 
frequency. While a large sample size is needed to validate all of the genotype 
combinations, this study highlights the simplicity and reliability of this method to predict 
drug efficacy and toxicity. Further improvements and application of this method will 
ultimately allow medical staff to quickly and easily evaluate patient genotypes, resulting 
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Fig. 1 Schematic diagram of a single-stranded tag hybridization chromatographic printed-
array strip (STH-PAS). (A-D) Test line positions on the STH-PAS. Red lines indicate 
positional markers. 
 
Fig. 2 Representative PCR amplicon signals using STH-PAS. Data represent independent 
replicates. Top panels show representative images of the STH-PASs, while the bottom 
graphics provide a summary of the genotype by lane. NC, negative control; Wt, template 
non-carrying mutation; Vr, template carrying mutation; Del, template carrying CYP4F2 




Table 1. PCR primers 
Target gene Position Primer name Primer sequence (5′ to 3′) Size (bp) 
VKORC1 -1639G>A (rs9923231) VKORC1_Fw_Wt_G [Tag 1]-X-CCTGAAAAACAACCATTGGCGG 348 
  VKORC1_Fw_Vr_T [Tag 4]-X-CCTGAAAAACAACCATTGGCTA  
  VKORC1_Rv [Biotin]-CACCAAGACGCTAGACCCAATG  
CYP2C9 42614A>C CYP2C9_Fw_Wt [Tag 5]-X-GCACGAGGTCCAGAGATACA 180 
 (CYP2C9*3, rs1057910) CYP2C9_Fw_Vr_G [Tag 8]-X-GCACGAGGTCCAGAGATAGC  
  CYP2C9_Rv [Biotin]-ACCCGGTGATGGTAGAGGTTT  
CYP4F2 18000G>A CYP4F2_Fw_Wt [Tag 10]-X-CATCACAACCCAGCTG 470 
 (CYP4F2*3, rs2108622) CYP4F2_Fw_Vr [Tag 12]-X-CATCACAACCCAGCTA  
  CYP4F2_Rv [Biotin]-AGGACCAACCCAACCG  
 Deletion CYP4F2_Del_Fw [Tag 11]-X-TTCCCGCCAAACCACTC 395 
32 
 
  CYP4F2_Del_Rv [Biotin]-TGCTCTTGAACAACCAATGG  
NUDT15 415C>T NUDT15_Fw_Wt [Tag 1]-X-CTTTTCTGGGGACTGC 403 
 (NUDT15*3, rs11655232) NUDT15_Fw_Vr [Tag 2]-X-CTTTTCTGGGGACTGT  
  NUDT15_Rv [Biotin]-GCAAGCTAGTAATGACAAACTGCAC  
ABCC4 2268G>A (rs3765534) ABCC4_Fw_Wt [Tag 7]-X-GGAGGAGGAAATGTAACCG 433 
  ABCC4_Fw_Vr [Tag 8]-X-GGAGGAGGAAATGTAACCA  
  ABCC4_Rv [Biotin]-ATTGGAACCATCCGAACCAC  
G6PD 202G>A (rs1050828) G6PD_202_Fw_Wt [Tag 1]-X-GCCCGAAAACACCTTCATCG 249 
  G6PD_202_Fw_Vr [Tag 2]-X-GCCCGAAAACACCTTCATCA  
  G6PD_202_Rv [Biotin]-GGGCTGGTAATGGGGGTCTC  
 376A>G (rs1050829) G6PD_376_Fw_Wt [Tag 3]-X-GCCTCAACAGCCACATGA 145 
  G6PD_376_Fw_Vr [Tag 4]-X-GCCTCAACAGCCACATGG  
33 
 
  G6PD_376_Rv [Biotin]-GGCAACGGCAAGCCTTAC  
mtDNA 1555A>G (rs267606617) Mt_Fw_Wt_T [Tag 1]-X-CCAGTACACTTACCATGTTACGACTTTT 146 
  Mt_Fw_Vr_T [Tag 4]-X-CCAGTACACTTACCATGTTACGACTTTC  
  Mt_Rv [Biotin]-TAAGAGTAGAGTGCTTAGTTGAACAGGG  
“X” represents “spacer C3”. The spacer C3 [three-carbon spacer, (CH2)3, using Phosphoramide C3 spacer] is inserted between the Tags and the respective 
forward primer. According to each genetic polymorphism, the nucleotides at the 3′ end of each forward primer were changed to match each sequence. The 
underlined nucleotides just before the 3′ end of these primers (VKORC1_Fw_Wt_G, VKORC1_Fw_Vr_T, CYP2C9_Fw_Vr_G, Mt_Fw_Wt_T, and 
Mt_Fw_Vr_T) indicate the differences made regarding the reference sequences in order to avoid non-specific amplification. 
 
